ABSTRACT
The aim was to investigate the expression of the CXCR4 protein in five molecular subtypes of breast cancer. The authors randomly selected the breast cancer paraffin-embedded specimens of the Affiliated Third Hospital of Harbin Medical University between 2007 and 2009. Details are as follows: basal-like subtype-ER (-), PR (-), C-erbB-2 (-), CK5/6 (+), n = 36; normal breast subtype-ER (-), PR (-), C-erbB-2 (-), CK5/6(-), n = 40; luminal A subtype-ER/PR (+), C-erbB-2 (-), n = 38; luminal B subtype-ER/PR (+), C-erbB-2 (+), n = 60; C-erbB-2 (+) subtype-ER (-), PR (-), C-erbB-2 (+), n = 58. Using the immunohistochemistry method, the authors detected the expression of the CXCR4 protein in the five subtypes. The CXCR4 protein expression in the basal-like subtype was the highest, and that in the luminal A subtype was the lowest. In terms of five molecular subtypes of breast cancer, the differences in CXCR4 protein expression were significant (p < .001). In terms of C-erbB-2 expression, tumor stage, and lymph node metastasis of breast cancer, the differences in CXCR4 protein expression were significant (p < .01).
Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/chemistry , Receptors, CXCR4/analysis , Breast Neoplasms/classification , Breast Neoplasms/pathology , Chi-Square Distribution , Female , Humans , Immunohistochemistry , Keratin-5/analysis , Keratin-6/analysis , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Prognosis , Receptor, ErbB-2/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysisABSTRACT
PURPOSE: The clinical features and prognosis of mucinous breast carcinoma (MBC) are unclear because of its rarity. The aim was to describe the clinicopathological features and prognosis of patients with MBC in comparison with nonmucinous breast carcinoma (NMBC). Furthermore, we described the biological behavior of pure mucinous breast carcinoma (PMBC) by comparing clinicopathological features and prognosis with mixed mucinous breast carcinoma (MMBC). METHODS: We reviewed the records of 5,872 consecutive patients diagnosed with breast carcinoma who were resected surgically from March 2003 to October 2010. Among them, 117 patients with MBC were compared to 5,575 patients with NMBC. Furthermore, 88 patients with PMBC were compared to 29 patients with MMBC. RESULTS: There were statistical differences in age, pN stage, ER level, and PR level between the patients with MBC and NMBC. There were statistical differences in pT stage and pN stage between the patients with PMBC and MMBC. The overall five-year survival of patients with MBC was 88.1 % as compared with 81.9 % for patients with NMBC. The overall five-year survival of patients with PMBC was 91.3 % as compared with 80.4 % for patients with MMBC. The overall five-year survival of patients with PMBC was 91.3 % as compared with 81.9 % for patients with NMBC. CONCLUSIONS: PMBC tended to have a better prognosis in comparison with other types of breast carcinoma.
Subject(s)
Adenocarcinoma, Mucinous/mortality , Breast Neoplasms/mortality , Carcinoma, Ductal, Breast/mortality , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Mucinous/therapy , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/therapy , Case-Control Studies , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Prognosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Retrospective Studies , Survival RateABSTRACT
BACKGROUND: We examined mRNA expression for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 in human breast cancer tissues, and the association between their expression and clinicopathological variables. PATIENTS AND METHODS: Breast tissue samples from 120 patients with breast cancer were available for this study. To determine mRNA expression for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out on tumor and normal tissues, respectively. RESULTS: Mean MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression in the breast cancer was significantly higher than in the normal tissue. In terms of tumor size and lymph node metastasis of breast cancer, the differences in MMP-2, MMP-7, MMP-9, and MT1-MMP mRNA expression levels were significant. CONCLUSION: The association between the increased expression of MMP-2, MMP-7, MMP-9, and MTI-MMP and clinicopathological parameters reflects a role in predicting the aggressive behavior of breast cancer.